Directory of Pharma Companies and News
Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofiâ€™s programs in oncology and immunology.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
|2018-06-04||New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squam...|
|2018-05-21||New England Journal of Medicine publishes two positive Phase 3 trials showing DupixentÂ® (dupilumab) improved moderate-to...|
|2018-05-16||DupixentÂ® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe ato...|
|2018-05-16||First positive clinical data for cemiplimab in advanced non-small cell lung cancer to be shared at ASCO|
|2018-04-30||FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma|
|2018-04-23||Treatment Effects Maintained over Seven Years in Patients with Relapsing Remitting Multiple Sclerosis Who Received Lemtr...|
|2018-04-23||Relapsing MS Patients Who Switched to AubagioÂ® (teriflunomide) Reported Increased Treatment Satisfaction in Two Clinical...|
|2018-04-19||More Than 25 Data Presentations from Sanofi Genzymeâ€™s Multiple Sclerosis Franchise to Be Featured at AAN|
|2018-04-06||Sanofi presents new data at AACR 2018 highlighting advances in early-stage oncology portfolio|
|2018-04-03||EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma|